picked up $10 million to fund the clinical development of its stem cell-derived treatment for patients who have Type 1 diabetes and are at risk of complications.
Specifically, the funds will be used to develop the company’s PEC-Direct candidate, which treats diabetes by administering stem cell-derived pancreatic progenitor cells in an implantable device, according to a statement. These cells are designed to mature into human pancreatic cells, including insulin-secreting beta cells.
This treatment is intended for high-risk Type 1 diabetes patients—those who experience severe hypoglycemic episodes, who have “brittle diabetes,” where blood glucose levels swing up and down, or who are less able or unable to spot symptoms of low blood sugar. ViaCyte plans to deliver the therapy alongside immune-suppressive drugs to prevent rejection.
“High‐risk type 1 diabetes has been successfully treated with cadaver islet transplants, but adoption of islet transplants…